* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Central venous catheters
Survey
Document related concepts
Transcript
Central venous catheters February 2010 Anne Aspin Central venous catheter • Central venous access is the placement of a venous catheter in a vein that leads directly to the heart. Site • Basillic or long saphenous vein preferred. • NB. Blood or blood products should not be infused. Catheter may rupture or block. • Catheter should always be flushed with 10 ml syringe Which vein to cannulate • Veins commonly lie close to arteries and nerves • Subclavian vein lies close to dome of pleura, damage lead to pneumothorax Types used • Percutaneous long lines • Percutaneous multi lumen lines • Peripheral inserted central catheter (PICC) • Broviac and Hickman lines • Portacath Length of time to use • Percutaneous line. • 10 – 12 weeks • Percutaneous multi lumen line • 5 – 10 days post operation • PICC line • 10 / 12 weeks • Broviac / Hickman line / Portacath • For long term use Percutaneous long line • TPN • Clear fluids • Medications - infuse slowly PICC • TPN • Clear fluids • Blood transfusion • Medications • Flush off Broviac / Hickman / Portacath • TPN • Clear fluids • Blood transfusion • Medications Percutaneous Multi lumen line • TPN • Clear fluids • Blood transfusion • Medications • Caution, ports 1, 2, 3 Complications • • • • • • • Sepsis Embolus Malposition Occlusion Fibrin sheath formation Dislodge rupture • • • • • • • • Thrombus Pneumothorax Perforation of vessel Cardiac tamponade Endocarditis Vent arrythmia Phlebitis Cuff erosion Sepsis • • • • • • Pyrexia, >38c Labile temperature Labile sugars Shock, pallor Apnoea tachycardia • Bradycardia • Capillary venous • • • return > 4 secs Grey Quiet thrombocytopenia Infection • Life threatening where neutriphil counts <500 cells/mm. • Local infection – exit site, port pocket and tunnel infection. • Systemic infection, colonised thrombi or fibrin sleeves • Intraluminal or extraluminal colonisation Infection • Gram –ve aerobes from gastro intestinal tract • E. coli, klebsiella, pseudomonas 25-33pc • Gram pos aerobes, Staph aureus,staph epidermis, strep 50pc • Candida 5-7pc • Greater risk infection with multi lumen catheter • In one study removed 139 days earlier. • Implanted port less infections • Extraluminal clot at catheter tip –related to cath related sepsis. • Pseudomonas difficult to eradicate • Antibiotics down the line • Locking catheter for two hours could eradicate pseudomonas, not confirmed in human studies. • ?Trial, Benefit / risk antibiotic resistance. Catheter occlusion • Cannot draw back nor solutions infuse • Usually clotted blood, precipitate • Flush well after sampling • Streptokinase, Urokinase – fibrinolytic agents. • • 5000 units per 1 cc 1ml each lumen, 4 hours. Check pharmacy. Takes 27 minutes, leave 60 mins. Extravasation • Leakage from vein into subcutaneous space • Pain, irritation in chest, swelling, necrosis • Crying, fussy, distressed. Catheter malposition • Painful phlebitis • Thrombosis • Backtracking • Pericardial effusion • Cardiac tamponade chest pain, shortness of breath. Cochrane review 2004 • Perc CVC versus peripheral cannula • RCTs • 3 trials for inclusion • CVC does improve nutrient input • No evidence of CVC increased risk of adverse events, ie infection. Percutaneous CVC • infants <1000g 28g single lumen, 20cm long maximum flow 38mls / hr. • Premicath 27g, markings every 5cm, max flow rate 30ml / hr Percutaneous CVC • Infants > 1000g, 24g, 30cms long, max flow 50 ml/hr • PICC, 20g, silicone, 50cm long • Epicutaneo Neocath, silicone, 30cm and 50cm length. Max flow 100ml/hr. Perc CVC removal • Use no longer justified • Bacteraemia beyond 48-72 hrs despite appropriate antibiotics • Septicaemia due to fungal infection • Evidence of septic emboli or endocarditis Broviac / Hickman line • Soft silicone • Tunneled • Buried under skin • Tissue grows around cuff to secure in place. • Cuff acts as barrier to infection • Can be flushed off. Dressings • Evidence. • Transparent / gauze / no dressing • Change dressing daily until dry then change twice weekly. • Chlorhexidine 1:200, 70% alcohol Portacath • Chemotherapy • Medications • For cancer or leukaemia • Soft plastic tube, disc between 2.5-4cm. • Catheter tunneled • Years. Discreet Ultrasound devices • Systematic review 2003 • Objective. To investigate clinical and cost- effectiveness of ultrasonic locating devices. • Ultrasound – two dimensional image • Dopplers – audible sound from venous blood flow Result • Twenty RCTs • Sample size small • < ten pounds per procedure • For every 1000 procedures, ?save 2000 • Improved failure and complication rate. References • Adler A, Yaniv I, Steinberg R, Solter E, Samra Z, Stein J, Levy I • • • • (2005). Infectious complications for implantable parts and Hickman catheters in paediatric haematology oncology patients. Journal of Hospital Infection. 62 : 358 - 365 Alexander N (2010). Question 3. Do Portocaths or Hickman lines have a higher risk of catheter-related bloodstream infections in children with leukaemia. Archives of Disease in Childhood. 95 : 239 - 241. doi:10.1136/adc2009.176545 Larson S, Hebra A, Raju R, Lee S (2010). Vascular Access, Surgical treatment. http://emedicine.medscape.com/article/1018395overview McIntosh W (2003). Central venous catheters : reasons for insertion and removal. Paediatric Nursing. Vol 15, No 1 Simon A, Ammann R, Wiszniewsky G, Bude U, Fleischhack G, Besuden M (2008). Taurolidine-citrate lock solution (Taurolock) significantly reduces CVAD - associated grampositive infections in paediatric cancer patients. BMC Infectious Diseases. 8 : 102